Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 850338 | Other Identifier | University of Pennsylvania |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. | Other | Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. |
| Measure | Description | Time Frame |
|---|---|---|
| Collecting, processing and archiving breast cancer tumor tissues | This study will collect and analyze tumor samples from women diagnosed with primary breast cancer. The investigators will dissociate fresh tumor samples and analyze single cell suspensions by flow cytometry. Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between breast cancer subtypes (HR+HER2-, HER2+, triple negative). Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between HR+HER2- untreated breast cancers compared to HR+HER2- chemotherapy treated breast cancers. | Through study completion, average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Associating breast cancer dendritic cell infiltrate with outcome | We will perform studies to associate dendritic cell infiltration and activation markers with patient outcome, including disease free survival, distant disease free survival, and overall survival. | 5 years |
Not provided
Inclusion criteria:
Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
Exclusion criteria:
Males Children Pregnant individuals
Not provided
Not provided
Not provided
Women 18 years of age or older undergoing surgery for breast cancer.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julia T. Lewandowski | Contact | 215-662-2861 | Julia.Lewandowski@Pennmedicine.upenn.edu | |
| Jennifer Zhang, MD | Contact | 215-615-6810 | Jennifer.Zhang@Pennmedicine.upenn.edu |
| Name | Affiliation | Role |
|---|---|---|
| Jennifer Zhang, MD | Abramson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Abramson Cancer Center | Recruiting | Philadelphia | Pennsylvania | 19104 | United States |
Individual participant data will not be shared with other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Tissue from breast tumors removed as standard of care treatment for breast cancer.
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D064726 | Triple Negative Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided